Targeting HER2-low in metastatic breast cancer: An evolving treatment paradigm Review
| Authors: | Yang, C.; Brezden-Masley, C.; Joy, A. A.; Sehdev, S.; Modi, S.; Simmons, C.; Henning, J. W. |
| Review Title: | Targeting HER2-low in metastatic breast cancer: An evolving treatment paradigm |
| Abstract: | The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. Herein, we discuss the evolving therapeutic pathway for HER2-low disease, ongoing clinical trials, and the potential challenges and evidence gaps arising with treatment of this patient population. © The Author(s), 2023. |
| Keywords: | chemotherapy; metastatic breast cancer; her2-targeted therapy; sacituzumab govitecan; trastuzumab deruxtecan; her2-low; treatment sequencing |
| Journal Title: | Therapeutic Advances in Medical Oncology |
| Volume: | 15 |
| ISSN: | 1758-8340 |
| Publisher: | Sage Publications Ltd. |
| Date Published: | 2023-01-01 |
| Start Page: | 17588359231175440 |
| Language: | English |
| DOI: | 10.1177/17588359231175440 |
| PROVIDER: | scopus |
| PMCID: | PMC10262633 |
| PUBMED: | 37323186 |
| DOI/URL: | |
| Notes: | Source: Scopus |
